- Ephidryomas
- Astrocytomas
- Oligodendrogliomas
Glioma refers to the broad category of the brain and spinal cord tumors, arises from the glial cells of the brain. Many types of gliomas based on the brain cell,Astrocytomas, Ephindryomas,andOligodendrogliomas. The symptoms, prognosis,and treatment of the gliomadepend on the patients age, exact type of tumor and location of tumor within brain. Chemotherapy or targeted drug therapy usually suggest for the treatment of glioma. Furthermore, treatment may include radiation therapy followed by surgery.
Key Developments:
- In March 2017, Sapience Therapeutics, Inc., announced that its lead candidate, ST-36, received orphan drug designation by the U.S. FDA the treatment of glioma.
- In September 2017, VAXIMM AG announced that the Companys lead product candidate, VXM01, received orphan designation from the European Commission and from the US Food and Drug Administration (FDA) for the treatment of glioma.
Glioma Pipeline Drugs Assessment Dynamics
Glioma Pipeline Drugs Assessment report studies the various therapeutics under clinical development for glioma treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the glioma pipeline drugs development. This report studies the dynamics of the Glioma Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on glioma pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.
Glioma Pipeline Drugs Assessment Segmentation
By Glioma Type
By Grade
- High-Grade Glioma
- Low-Grade Glioma
By Trial Phase
- Preclinical Studies
- Phase-I
- Phase-II
- Phase-III
- Phase-IV
Frequently Asked Questions
2021 is the base year and 2028 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
| 1. Executive Summary |
| 2. Global Glioma Pipeline Drugs Assessment Market Introduction |
| 2.1.Global Glioma Pipeline Drugs Assessment Market - Taxonomy |
| 2.2.Global Glioma Pipeline Drugs Assessment Market - Definitions |
| 2.2.1.Glioma Type |
| 2.2.2.Grade |
| 2.2.3.Trial Phase |
| 3. Global Glioma Pipeline Drugs Assessment Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4. Global Glioma Pipeline Drugs Assessment Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Glioma Pipeline Drugs Assessment Market By Glioma Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Ephidryomas |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Astrocytomas |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Oligodendrogliomas |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 6. Global Glioma Pipeline Drugs Assessment Market By Grade, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. High-Grade Glioma |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Low-Grade Glioma |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 7. Global Glioma Pipeline Drugs Assessment Market By Trial Phase, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. Preclinical Studies |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Phase-I |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Phase-II |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Phase-III |
| 7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Phase-IV |
| 7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 8. Competition Landscape |
| 8.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 8.2.1.GW Pharmaceuticals (UK) |
| 8.2.2.Daiichi Sankyo Company (Japan) |
| 8.2.3.Sapience Therapeutics, Inc. (U.S.) |
| 8.2.4.Tocagen (U.S.) |
| 8.2.5.Vaximm AG (Switzerland) |
| 8.2.6.Tocagen (U.S.) |
| 9. Research Methodology |
| 10. Appendix and Abbreviations |
- GW Pharmaceuticals (UK)
- Daiichi Sankyo Company (Japan)
- Sapience Therapeutics, Inc. (U.S.)
- Tocagen (U.S.)
- Vaximm AG (Switzerland)
- Tocagen (U.S.)